Recipharm Appoints New Position of Vice President Quality Management
![](/46/pdcnewsitem/03/42/58/s4EBaz2btx0DUbx.png)
Recipharm has appointed Thomas Beck to the new senior role of Vice President Quality Management (VP QM) with effect from 1st April 2015. Thomas is currently Head of Quality Control and Assurance at Recipharm Stockholm, a position that he has held since 2010. He is also Chairman of the Quality Assurance section within the Swedish Academy of Pharmaceutical Science.
In this new role Thomas will drive and co-ordinate the quality strategy and policy across the Recipharm Group subsidiaries and assist the Group Management Team (GMT) in monitoring and evaluating the company’s quality efforts. He will also lead the company’s audit process and support the sales activity by providing a primary contact point for new customers’ regulatory and quality affairs departments.
Reporting to the EVP Chief Operation Officer, this post represents an expansion of the Group Management Team in a move designed to help it meet the increased demands the group is facing following the recent rapid growth.
Commenting on the new appointment, Thomas Eldered, CEO of Recipharm, remarked: “This new position will bolster and enhance the work of the Group Management Team, meeting head on the quality management challenges our industry faces. Thomas will take a pivotal role in ensuring that we deliver and practice the highest standards of quality right across the entire Recipharm Group. He personally brings strong quality management expertise and already has specific experience of operations at Recipharm and the high standards that we are committed to delivering for our customers. I very much look forward to his authoritative support and direction being brought to bear for the benefit of the Group as a whole.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance